Diverging likelihood of colon and rectal cancer in Yogyakarta, Indonesia: A cross sectional study
by Herindita Puspitaningtyas, Susanna Hilda Hutajulu, Jajah Fachiroh, Nungki Anggorowati, Guardian Yoki Sanjaya, Lutfan Lazuardi, Patumrat Sripan
ObjectivesColon and rectal cancer are associated with different risk factors and prognostic. However, this discrepancy has not been widely explored in the local population. This study aimed to investigate the site-specific likelihood of colorectal cancer (CRC) incidence in the Yogyakarta province, Indonesia.
MethodsThis cross-sectional study analyses 1,295 CRC cases diagnosed in 2008–2019 registered in the Yogyakarta population-based cancer registry (PBCR) database. Cases were grouped into colon and rectal cancer. Log-binomial regression was used to determine the relative risk of either colon or rectal cancer across different gender, age group, and rurality of residence. The age-specific rates were calculated by age group and temporal trend for each group were analyzed using joinpoint regression.
ResultsFemales displayed higher odds of colon cancer (relative risk/RR = 1.20, 95%CI = 1.02–1.41) and lower odds of rectal cancer (RR = 0.92, 95%CI = 0.85–0.99). Elevated odds of colon cancer were observed in younger age group, especially 30–39 (RR = 1.87, 95%CI = 1.10–3.19), while decreased odds of rectal cancer was apparent in age group 30–39 and 40–49 (RR = 0.75, 95%CI = 0.60–0.93 and RR = 0.82, 95%CI = 0.69–0.98, respectively). Living in urban or rural areas did not significantly influence the odds of either having colon (RR = 0.98, 95%CI = 0.82–1.17) or rectal cancer (RR = 1.01, 95%CI = 0.93–1.10). During 2008–2019, trends of colon cancer in age <50 increased by 8.15% annually while rectal cancer displayed a 9.71% increase annually prior to 2017, followed by a 17.23% decrease until 2019.
ConclusionsYogyakarta population shows higher odds of young-onset colon cancer, especially between age 30–39 years old. Overall observation of trend shows increasing incidence in young-onset colon cancer, and non-significant decrease in rectal cancer.